L	Therapeutic Agent	Treatment of Poisoning by:		Minimum # units for each HCF category*					Needs Assessment for Health Care Facilities (HCF)
			Unit size	Main Depot	Local Depot	Hospital ≤ 1 hr from Depot	Hospital > 1 hr from Depot	Treat- ment Centre	* Minimum # of units to treat ONE 70 kg patient. Greater than one patient supply may required, according to case volume. A "Treatment Centre" is a HCF which provides emergency care, but lacks inpatient beds.
	ctivated Charcoal	toxins which are bound by charcoal	50 g/250	8	6	3	3	3	Most HCF require inventory for 2 or more patients.
	cetylcysteine Inj	acetaminophen	mL bottle 2g/10 mL	30	20	15	15	10	Most HCF require inventory for 2 or more patients; a 1 patient supply is sufficient for most treatment centres.
		•	vials						
Α	tropine sulfate Inj	organophosphate & carbamate insecticides	0.6mg/mL amp	150	150	50	150	50	High doses may be required for organophosphate poisonings: 150 amps (90 mg) may be required to treat a 70 kg victim organophosphate poisoning for approximately 8 hours.
С	alcium Gluconate Inj	HF acid burns (topical, SC)	1g/10mL vial	10	10	10	10	10	Stocking both calcium salts is recommended; however, if only stocking one agent then calcium gluconate should be stock Chloride salt preferred for calcium channel blocker overdose; gluconate preferred for topical use or SC infiltration in hydrol acid burns. Note: chloride provides 3x more calcium per gram than gluconate stort.
С	alcium Chloride Inj	calcium channel blockers	1g/10mL PFS	20	20	10	10	10	
D	igoxin Immune Fab Inj	digoxin/digitalis glycosides	40mg/vial	10	10	5	5	0	Recommended at all HCF able to measure serum digoxin levels. Optional for HCF without on-site digoxin levels if use is infrequent AND a supply can be obtained from a neighbouring HCF within ~1 hour.
F	omepizole Inj	methanol, ethylene glycol	1500 mg/ vial	4	2	1	1-2	1	Remote HCF that are prone to transportation delays require 2 vials.
F	lumazenil Inj	benzodiazepines	0.5 mg /5 mL vial	10	10	5	10	5	Rarely indicated. May be used to prevent the need for intubation in patients, or for management of paradoxical excitation.
G	lucagon Inj	calcium channel blocker, beta-blocker	1mg/vial	60	40	15	20	0	Newer therapies (e.g. insulin/glucose) for calcium channel blocker overdose do NOT eliminate the need to stock glucago
	ydroxocobalamin Evanokit®) Ini	cyanide, acetonitrile	5 g/ vial	2	1	1	1	1	Should be considered for victims of smoke inhalation.
	larucizumab	dabigatran bleeding reversal	2.5 g/ 50 mL	2	2	2	2	2	Reversal for emergency surgery/urgent procedures or in life-treatening or uncontrolled bleeding in patients taking dabigate Dose is 5 q (2 vials).
Li	ipid Emulsion	Local anesthetics, other cardiotoxic medications	2x250 mL or 500 mL bag	1	1	1	1	0	Reserved for cardiotoxicity not responding to standard rescucitation guidelines.
M	lethylene blue Inj	methemoglobinemia	50 mg/5 mL amp	10	10	5	5	3	Common causes of methemoglobinemia: nitrites, dapsone, local anesthetics, phenazopyridine.
N	aloxone Inj	opiates, opioids	0.4mg /1mL amp	100	100	100	100	100	Most HCF require inventory for 2 or more patients. With the more potent fentanyl analogues, patients may require up to 1 and then may need to be on an infusion afterwards.
P	yridoxine Inj	high dose isoniazid (seizures)	3 g/ 30 mL vial	5	4	2	2	2	
	lack widow spider ntivenin Inj		1 vial (2.5 mL)	2	1	0	0	0	SPECIAL ACCESS PROGRAMME Manufacturer keeps a supply in Montreal.
	rotalidae Polyvalent ab Antivenin Inj	rattlesnake (Crotalidae) envenomation	1 vial	24	12	6	12	0	SPECIAL ACCESS PROGRAMME (US supplier) HCF fulfilling any one of the following criteria: A) located in region whi rattlesnakes are indigenous [In BC, southern and central interior, map available from DPIC] B] catchment area includes a lipopulation of captive rattlesnakes (e.g. aquarium, nature park, academic institution). C) 3° HCF which may receive snak withins transferred from other regions.
D	eferoxamine Inj	iron	500mg /vial	30	20	10	15	10	
D	imercaprol (BAL) Inj	lead, mercury, arsenic	300 mg/ 3 mL amp	10	0	0	0	0	Distribute depots such that the chelating agent could be administered within 6 hours, assuming that the most rapid form or emergency transport will be used to transport either the patient or the drug. One depot required a
F	olic Acid Inj	methanol	50mg/ 10mL vial	8	8	4	6	2	Folic acid <i>cannot</i> be substituted for <b>leucovorin</b> in management of methotrexate exposure. BOTH forms of folate are recommended.
L	eucovorin Inj	methotrexate, methanol	50mg /5mL vial	2	1	1	1	1	
0	ctreotide Inj	sulfonylurea (hypoglycemia)	100 μg/ 1mL amp	10	6	3	3	3	
P	EG Solution	iron, some SR preparations, some metals	4 L jug	6	6	2	3	2	Larger quantity for remote sites at risk for delayed transfer.
P	ralidoxime Inj	organophosphate insecticides	1g/vial	24	12-24	3	6	0	SPECIAL ACCESS PROGRAMME (through Baxter in Ontario)
P	rotamine Sulfate Inj	heparin	50mg /5mL vial	10	5	2	3	2	
V	itamin K1 Inj	warfarin, rodenticides	10mg/1mL amp	20	20	10	10	10	
C	alcium disodium EDTA	lead, zinc	10 mL amp (50 mg/mL)	Used parenterally for lead poisoning. Adult dose is 2-4 G IV daily for 5 days.			J. Adult dose	is 2-4 G IV	SPECIAL ACCESS PROGRAMME (Laboratoire Serb in France) Rarely used. Backordered indefinitely. Alternatives in dimercaprol and succimer.
С	yproheptadine	serotonin syndrome	4 mg tab	Adjunctive treatment of serotonin syndrome; limited evidence supporting effectiveness.			ndrome; limi	ted	May be recommended by toxicologists for severe serotonin syndrome. Other treatment options available. May be conside 3° and 2° HCF.
	antrolene Inj	malignant hyperthermia secondary to anesthetic	20mg/vial	Primarily used for anesthetic-induced malignant hyperthermia, rarely used for poisoning.					Required by all HCF using inhalation anesthetics.
	enicillamine	copper, lead, arsenic	250mg caps	Limited use as a chelating agent.					Can usually be purchased on an as needed basis.
P	otassium iodide	radioactive iodine	various	May be used for thyroid protection following exposure to radioactive iodine.				osure to	Various dosage forms available over the counter from US Manfuacturers (e.g. Thyrosafe®, Isosat®, Thyroshield®). Potas lodde can also be obtained from LugoTs solution or capsules may be compounded using potassium iodide crystals.
s	odium nitrite Inj	hydrogen sulfide	12.5 g/ 50mL vial	Adjunct to supportive care for hydrogen sulfide poisoning; limited evidence supporting effectiveness.				oisoning;	SPECIAL ACCESS PROGRAMME (through McKesson) Rarely used. May be kept at sites close to a hydrogen sulfide generating industry (e.g. oil and gas, mining, sewage treatment).
s	odium thiosulfate	cyanide, acetonitrile	300 mg/	May be used for cyanide poisoning; limited evidence.				nce.	SPECIAL ACCESS PROGRAMME (through McKesson) Rarely used. May be used for cyanide poisoning if hydroxocol
	uccimer	chelating agent for lead, mercury, arsenic	10 mL vial 100 mg cap						unavailable.  SPECIAL ACCESS PROGRAMME (US manufacturer) Canadian distributor is GMD Distribution.